MicroRNA 320b-2 (miR-320b-2)

MicroRNA 320b-2 (miR-320b-2, officially MIR320B2 or hsa-mir-320b-2) is a non-coding RNA molecule that belongs to the microRNA-320 family, which acts by regulating gene expression post-transcriptionally. It is not a classical drug target such as a receptor or enzyme, but it has been implicated as a potential biomarker and regulatory molecule in diverse biological processes. Increased expression of miR-320b (family) is associated with enhanced lymphangiogenesis, proliferation, migration, and epithelial-mesenchymal transition of tumor cells in esophageal squamous cell carcinoma through the PDCD4-AKT pathway, suggesting a role in cancer metastasis[1]. In metabolic diseases, miR-320 family members regulate glucose and lipid metabolism in adipocytes, cardiomyocytes, kidney, liver, and pancreas, and have been implicated in insulin resistance, diabetic cardiomyopathy, diabetic nephropathy, and hepatic insulin sensitivity[2]. Elevated miR-320b expression has also been observed in blood plasma of COVID-19 patients, where it is associated with disease severity and prognosis, likely by modulating inflammatory and antiviral defense pathways[3]. Although described as a potential therapeutic target and biomarker in these contexts, there are no direct-approved drugs targeting miR-320b-2, nor is it considered a canonical "therapeutic target" in the sense of a receptor or enzyme. The name "miR-320b-2" mirrors the unconventional but systematic nomenclature for microRNA loci and not gene/protein targets relevant to small-molecule or antibody drugs. Note: There is insufficient evidence for the direct existence of "microRNA 320b-2" (MIR320B2) as a functionally distinct target apart from the broader miR-320b family. Commonly, the literature discusses "miR-320b," not "miR-320b-2" specifically. This may indicate a confusion between family members, genomic loci, or mature/precursor microRNA nomenclature, and there is no evidence for any direct drug interaction, receptor function, or protein-coding role. Thus, "MIR320B2" is not a conventional therapeutic target and might be an incorrect or excessively granular designation[1][2][3].

Other names

hsa-mir-320b-2MIR320B2